Servier

Servier acquired KER-0193 from Kaerus Bioscience for up to $450 million, marking the company's first neurology asset acquisition as part of its 2030 strategy to establish a leading neurology franchise.

Servier and IDEAYA Biosciences announced an exclusive licensing agreement worth up to $530 million for darovasertib, a protein kinase C inhibitor targeting uveal melanoma, a rare and aggressive eye cancer.

Allogene Therapeutics narrowed its GAAP net loss to $0.23 per share in Q2 2025, beating estimates of $0.27 per share while maintaining a strong cash position of $302.6 million.

The European Medicines Agency's CHMP has issued a positive opinion recommending approval of vorasidenib (Voranigo) for treating grade 2 IDH-mutant glioma in patients aged 12 years and older following surgical resection.

The phase 3b ProvIDHe study demonstrated that ivosidenib achieved a median progression-free survival of 4.7 months and overall survival of 15.5 months in patients with IDH1-mutated cholangiocarcinoma.

BioMed X and Servier have launched the first XSeed Labs in Europe at the Spartners incubator in Paris-Saclay, implementing a crowdsourcing model that embeds academic researchers within pharmaceutical R&D facilities.

A post-hoc analysis of the Phase III NAPOLI 3 trial identified characteristics associated with long-term survival in metastatic pancreatic adenocarcinoma patients treated with the NALIRIFOX regimen.

Servier will showcase its precision medicine research for IDH-mutated cancers at the 2025 ASCO Annual Meeting in Chicago, focusing on chondrosarcoma, cholangiocarcinoma, and myelodysplastic syndrome.

• Servier has secured global rights to develop and commercialize BDTX-4933, a Phase 1 targeted therapy designed to address both RAS mutations and RAF alterations in solid tumors, particularly non-small cell lung cancer. • The agreement includes a $70 million upfront payment to Black Diamond Therapeutics, with potential for up to $710 million in additional milestone payments plus tiered royalties on global sales. • BDTX-4933 is currently in Phase 1 trials evaluating safety, dosing, and efficacy in patients with advanced cancers harboring BRAF, CRAF, or NRAS mutations, positioning it as a potential best-in-class treatment for RAF/RAS-mutant solid tumors.

• Medable Inc. has received CNIL approval to operate its eConsent and eCOA solutions in eight countries outside the EU, marking a significant expansion of digital clinical trial capabilities. • The company partnered with French pharmaceutical giant Servier to achieve this regulatory milestone, demonstrating platform validation and enhanced security measures through a rigorous six-month process. • Medable's digital platform has shown impressive results across 300+ trials globally, including 90% eCOA adherence and potential ROI of up to $39 million for Phase III trials.